Immunosuppressive standards in simultaneous kidney-pancreas transplantation

Clinical Transplantation

Volumn 20, Issue SUPPL. 17, 2006, Pages 44-50

  Schmied, Bruno M ^a   Muller S A ^a   Mehrabi, A ^a   Welsch, Th ^a   Buchler M W ^a   Zeier, M ^a   Schmidt, J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Immunosuppression; Induction therapy; Maintenance therapy; Pancreas transplantation

Indexed keywords

15 DEOXYSPERGUALIN; ANTIMETABOLITE; AZATHIOPRINE; BREQUINAR; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; FINGOLIMOD; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR BLOCKING AGENT; LEFLUNOMIDE; MALONONITRILAMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; RECEPTOR BLOCKING AGENT; THYMOCYTE ANTIBODY; TSUKUBAENOLIDE; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER TOXICITY; MAINTENANCE THERAPY; MEDICAL SPECIALIST; MORBIDITY; NEPHROTOXICITY; NEUROTOXICITY; OPPORTUNISTIC INFECTION; PANCREAS GRAFT REJECTION; PANCREAS TRANSPLANTATION; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; SURGICAL MORTALITY; SURGICAL TECHNIQUE;

GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PANCREAS TRANSPLANTATION;

EID: 33750742714     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2006.00599.x     Document Type: Article

References (40)

1. Kahan BD, Chiao P. The legendary exchange of hearts, traditional Chinese medicine and the modern era of cyclosporine. Transplant Proc 1988: 20: 3.
2. Hakim NS, Papalois VE. History of Organ and Cell Transplantation. London: Imperial College Press, 2003.
3. Kelly WD, Lillehei RC, Merkel FK et al. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery 1967: 61: 827.
4. Stratta RJ, Gaber AO, Shokouh-Amiri MH et al. Evolution in pancreas transplantation techniques: Simultaneous kidney-pancreas transplantation using portal-enteric drainage without antilymphocyte induction. Ann Surg 1999: 229: 701.
5. Lillehei RC, Simmons RL, Najarian JS et al. Pancreatico-duodenal allotransplantation: Experimental and clinical experience. Ann Surg 1970: 172: 405.
6. Sollinger HW, Cook K, Kamps D, Glass NR, Belzer FO. Clinical and experimental experience with pancreaticojejunostomy for exocrine pancreatic drainage in pancreas transplantation. Transplant Proc 1984: 16:749.
7. G ruessner RW, S utherland DE, T roppmann C et al. The surgical risk of pancreas transplantation in the cyclosporine era: An overview. Am J Coll Surg 1997: 185: 128.
8. Prieto M, Sutherland DE, Fernandez-C ruz L et al. Experimental and clinical experience with urine amylase monitoring for early diagnosis of rejection in pancreas transplantation. Transplantation 1987: 43: 73.
9. Cantarovich D, Giral-Classe M, Hourmant M et al. Low incidence of kidney rejection after simultaneous kidney-pancreas transplantation after antilymphocyte globulin induction and in the absence of corticosteroids: results of a prospective pilot study in 28 consecutive cases. Transplantation 2000: 69: 1505.
10. Borel JF, Feurer C, Gubler HU et al. Biological effects of cyclosporine A: A new antilymphocyte agent. Agents Actions 1976: 6: 468.
11. Merril JP, Murray JE, Harrison JH et al. Successful homotransplantation of the kidney between nonidentical twins. N Engl J Med 1960: 262: 1251.
12. Starzl TE, Marchioro TL, Homes JH et al. Clinical problems in renal homo-transplantation. J Am Med Assoc 1964: 187: 734.
13. Gruessner RW, Sutherland DER, Parr E et al. Improvements from steroid withdrawal after pancreas transplantation: 1-year results from a prospective, randomized open-label study. Am J Transplant 2001: 1: 158.
14. Malaise J, Nakache R, Kahl A et al. Corticosteroid withdrawal in simultaneous pancreas-kidney transplantation: A 3-year report. Transpl Proc 2005: 37: 2853.
15. Granelli-Piperano A, Nolan P, Inabak K et al. The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin 2 promotor. J Exp Med 1990: 172: 1869.
16. Hess AD, Tutschka PJ, Santos GW. Effect of cyclosporine on the induction of cytotoxic T lymphocytes: Role of interleukin-1 and interleukin-2. Transplant Proc 1983: 15: 2248.
17. Calne RY, Rolles K, White DJG et al. Cyclosporine A initially as the only immunosuppressant in 36 patients of cadaveric organs: 32 kidneys, 2 pancreas and 2 livers. Lancet 1979: 2: 1033.
18. Calne RY, White DJG, Thiru S et al. Cyclosporine A in patients receiving renal allografts from cadaver donors. Lancet 1978: Ii: 1323.
19. Fioretto P, Steffes MW, Mihatsch MJ et al. Cyclosporine associated lesion in native kidneys of diabetic pancreas transplant recipients. Kidney Int 1995: 48: 489.
20. Remuzzi G, Bertani T. Renal vascular and thrombotic effects of cyclosporine. Am J Kidney Dis 1989: 13: 261.
21. Burke GW, Alejandro R, Roth D et al. Use of FK 506 in simultaneous pancreas/kidney transplantation: Lack of impairment of glycemic or lipid metabolism. Transplant Proc 1995: 27: 3119.
22. Gruessner RW, Burke GW, Stratta R et al. A multicenter analysis of the first experience with FK 506 for induction and rescue therapy after pancreas transplantation. Transplantation 1996: 61: 261.
23. G ruessner RW. Tacrolimus in pancreas transplantation; a multicenter analysis. Tacrolimus Pancreas Transplant Study Group. Clin Transplant 1997: 11: 299.
24. C orry RJ, E gidi MF, S hapiro R et al. Pancreas transplantation with enteric drainage under tacrolimus induction therapy. Transplant Proc 1997: 29: 642.
25. Elmer DS, Abdulkarim AB, Fraga D et al. Metabolic effects of FK 506(takrolimus) versus cyclosporine in portally drained pancreas allografts. Transplant Proc 1998: 30: 523.
26. Jordan ML, Shapiro R, Gritsch HA et al. Long-term results of pancreas transplantation under tacrolimus immunosuppression. Transplantation 1999: 67: 266.
27. Sutherland DE, Gruessner RW, Dunn DL et al. Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann Surg 2001: 233: 463.
28. Odorico JS, Pirsch JD, Knechtle SJ, D'Alessandro AM, Sollinger HW. A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation. Transplantation 1998: 66: 1751.
29. Merion RM, Henry ML, Melzer JS et al. Randomized, prospective trial of mycophenolate mofetil versus azathioprine for prevention of acute renal allograft rejection after simultaneous kidney-pancreas transplantation. Transplantation 2000: 70: 105.
30. Elkhammas EA, Ylmaz S, Henry ML et al. Simultaneous pancreas/kidney transplantation. Comparison of mycophenolate mofetil versus azathioprine. Transplant Proc 1998: 30: 512.
31. Mc Alister VC, Gao Z, Peltekian K et al. Sirolimus-takrolimus combination immunosuppression. Lancet 2000: 355: 376.
32. Odorico JS, Pirsch JD, Becker YT et al. Experience with rapamycin in pancreas transplantation. Am J Transplant 2001: 1: 160.
33. Havrdova T, Saudek F, Boucek P et al. Metabolic effects of sirolimus versus mycophenolate mofetil on pancreatic graft function in the early posttransplant period. Transplant Proc 2005: 37: 3544.
34. Bruce DS, Woodle ES, Newell KA et al. Tacrolimus/mycophenolate mofetil provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation. Transplant Proc 1998: 30: 1538.
35. Hajjar MA, Chang GJ, Mahanty HD et al. Superior rejection rates with thymoglobulin induction in simultaneous pancreas-kidney transplantation. Am J Transplant 2001: 1: 327.
36. Hesse UJ, Troisi R, Jacobs B et al. A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants. Clin Transplant 2000: 14: 340.
37. Kaufman DB, Leventhal JR, Koffron AJ et al. A prospective study of rapid corticoid elimination in simultaneous pancreas-kidney transplantation: comparison of two maintenance immunosuppression protocols: Tacrolimus/ mycopeholate mofetil versus tacrolimus/sirolimus. Transplantation 2002: 73: 169.
38. Kaufman DB, Burke GW, Bruce DS et al. The role of antibody induction in simultaneous pancreas kidney transplant recipients receiving tacrolimus+ mycophenolate mofetil immunosuppression. Transplantation 2002: 69: 206.
39. Kaufman DB, Burke GW, Bruce DS et al. A prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas-kidney transplantation. Am J Transplant 2003: 3: 855.
40. G ruessner RW, S utherland ER. Transplantation of the Pancreas. New York: Springer-Verlag, 2004: 292.